Why one word took over regenerative medicine
Five years ago almost no patient walked into a clinic asking about exosomes. Today it is one of the most requested things we are asked about, and the reason is straightforward: the biology is interesting. Exosomes are extracellular vesicles, roughly 30 to 150 nanometres across, that cells release to talk to one another. They carry proteins, lipids and genetic material, and they appear to coordinate a large part of how tissue repair is organized. If you wanted to design a signaling therapy from scratch, you would design something that looks a lot like this.
Interesting biology is not the same as proven treatment, and the gap between those two things is where most patients lose money. This article is our attempt to close that gap honestly.
What the human data shows
Until recently the honest answer was that almost all exosome evidence came from cells in dishes and animals. That has changed. A systematic review and meta-analysis of human clinical trials published in the Aesthetic Surgery Journal in 2026 pooled the available studies in aesthetic medicine and found facial wrinkle reduction averaging 20.2 percent, with a 95 percent confidence interval of 15.3 to 25.2 percent. Additional skin outcomes (pigmentation, elasticity, texture, erythema and overall appearance) improved by between 14.7 and 23.4 percent. Hair density improved by 23.6 percent and hair thickness by 18.0 percent.
Those are real numbers from real people, and they are the strongest case anyone can currently make for exosomes. We are not going to pretend they do not exist.
What that 20 percent does and does not mean
It means a measurable, consistent improvement across several studies. It does not mean a guaranteed result for you. The same authors who reported those figures wrote that heterogeneity and non-standardized protocols limit generalisability, and they graded the level of evidence at 3, which is not the top tier. Different studies used different products, different doses, different delivery methods and different outcome scales. Pooling them gives you a signal, not a prescription.
It also means something specific about where the evidence is strongest: skin and hair, measured over months, in aesthetic settings. It is not evidence that exosomes treat arthritis, autoimmune disease, neurological conditions or anything else you may have read about online.
The regulatory reality nobody advertises
This part matters more than the efficacy numbers, and almost no clinic website mentions it. In December 2019 the FDA issued a public safety notification after multiple patients in Nebraska experienced serious adverse events following treatment with unapproved products marketed as containing exosomes. The agency stated that there are no FDA-approved exosome products, that exosomes used to treat disease are regulated as drugs and biological products subject to premarket review, and that clinics offering them outside that process are, in the agency's words, taking advantage of patients.
That notification has not been withdrawn. As of 2026 there is still no FDA-approved exosome product for any therapeutic use, although several candidates have entered formal clinical trials under investigational applications, which is exactly the process the agency described.
The placebo problem the whole field has to answer
There is a broader issue that applies to regenerative medicine generally, and the most rigorous work on it comes from the neighbouring stem-cell literature. A 2025 meta-analysis in Frontiers in Medicine examined randomized trials of mesenchymal stem cell injections for knee osteoarthritis and concluded that the majority of symptomatic improvement was attributable to contextual (that is, placebo) effects, with the cells themselves conferring only a modest incremental benefit.
Regenerative treatments are expensive, invasive-feeling and administered in impressive settings. All of those amplify contextual effects. A clinic that never raises this with you is either unaware of the literature or hoping you are.
How we decide whether to offer it to you
Five filters, in order. Is there a plausible mechanism for your specific goal? Is there human evidence in a population resembling you? Is there a better-established option we should try first? Have you been told, in plain language, what is investigational? And is the product from a source whose manufacturing and testing we can verify?
If a case fails those filters, we say no. We have declined to offer exosome protocols to patients who asked for them and were willing to pay, because the request did not match the evidence. That is not us being difficult. That is what you are paying a physician for.
What a responsible conversation sounds like
It sounds like this: here is what the pooled human data shows, here is the confidence interval, here is the regulatory status, here is the part that may be placebo, here is what it costs, here is what we will measure to know whether it worked, and here is the point at which we will stop if it has not. Then you decide.
If you have been offered exosome therapy elsewhere and want a second opinion before you commit, that is a reasonable thing to ask for and we are happy to give it, including if the answer is that we would not do it.
Evidence
What the research says
We cite the studies directly, including where the evidence is thin. Every link goes to the primary source.
Facial wrinkle reduction averaged 20.2% (95% CI, 15.3%-25.2%; P < .001). Additional skin-related outcomes improved by 14.7% to 23.4%, including pigmentation, elasticity, texture, erythema, and overall appearance.
Stack ER, Spongberg C, Braud SC, Stanton WN, Elway M. Clinical Advances in Exosome-Based Therapies for Aesthetic Medicine: A Systematic Review and Meta-analysis of Human Clinical Trials. Aesthetic Surgery Journal, 2026;46(Suppl 1):S13–S25.
The strongest human evidence currently available. The same authors rate the level of evidence at 3 and warn that non-standardized protocols limit generalisability, which is why we discuss exosomes as investigational.
There are currently no FDA-approved exosome products... The clinics currently offering these products outside of FDA's review process are taking advantage of patients and flouting federal statutes and FDA regulations.
U.S. Food and Drug Administration. Public Safety Notification on Exosome Products, 6 December 2019.
Issued after multiple patients experienced serious adverse events from unapproved exosome products. It has not been withdrawn. Any clinic that does not raise this with you is not giving you informed consent.
The majority of symptomatic improvement following intra-articular MSC injections is attributable to contextual (placebo) effects, whereas the MSCs themselves confer only a modest incremental benefit.
Yin F, Wu H, Tong D, et al. Contextual effects of mesenchymal stem cell injections for knee osteoarthritis: systematic review and meta-analysis of randomized controlled trials. Frontiers in Medicine, 2025.
From the neighbouring regenerative literature: eight randomized trials, 467 patients, with contextual factors accounting for roughly 63% of pain reduction at six months. We show you this because you deserve to see it before you spend money.
